Professor Reynolds states the product is a significant breakthrough in treating dengue fever, a disease transferred to humans through A.aegypti mosquitoes which is estimated to effect 390 million people every year and is particularly prevalent throughout Asia.
“Prior to 98alive there was no cure or vaccine against dengue fever which we felt needed to be addressed given that 40 per cent of the world’s population live in the dengue danger zone around the equator,” Reynolds said. “Adding to this, many of these at risk countries such as India and Indonesia also suffer high fatality rates due to current treatments not being affordable, effective or easily accessible.
“98alive is taken in capsule form, so it is easy to administer,” Reynolds continued. “It has been proven to commence elimination of the virus within ten minutes of being taken, which not only reduces the chance of the disease becoming life threatening but also prevents it from spreading.”
Reynolds states, “The medicine’s immune boosting properties means it is also highly effective in preventing dengue fever. 98alive primarily strengthens the immune system and therefore the recipient’s ability to fight the viral infection. This means that travellers or people living in at risk areas can take 98alive as a means of preventing dengue fever and to build up a resistance to the disease.”
This benefit of 98alive is particularly compelling given that the infection rate of dengue fever increased 30 fold from 1960 to 2010 and has been projected to increase even further as global warming causes the habitat for mosquitoes to expand. Reynolds states that 98alive’s unique make up of 98 active compounds is what makes it such an effective and fast acting treatment against the symptoms of dengue fever which include fever, headaches, muscle pain and rashes.
“Our unique process of distilling the Melaleuca alternifolia leaves ensures that the end result retains the plant’s highly beneficial antiviral, antibacterial, anti-inflammatory and antioxidant properties whilst removing the bulk of the potentially toxic monoterpene components that have, until now, prevented it from being consumed,” Reynolds said.
“98alive is the only Melaleuca alternifolia-based medicine that is listed on the Australian Register of Therapeutic Goods (Australian Licence 202131) and that is recognised by the United States’ Food and Drug Administration as safe for human consumption. Developed in Australia, which is known for its strict medical and product regulations, 98alive has undergone rigorous testing at world leading research facilities in Australia, the US and in Asia.
EP News Bureau – Mumbai